Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
BLPH Bellerophon Therapeutics
1.020
+0.004+0.39%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
6.52% 5.12M 25.16% 6.54M -3.70% 5.64M -23.27% 20.16M
Selling and administrative expenses
-22.96% 1.37M 3.32% 2.05M -45.80% 1.23M -14.79% 7.15M
-General and administrative expense
-22.96% 1.37M 3.32% 2.05M -45.80% 1.23M -14.79% 7.15M
Research and development costs
23.76% 3.75M 38.56% 4.49M 23.02% 4.41M -27.25% 13.02M
Operating profit
-6.52% -5.12M -25.16% -6.54M 3.70% -5.64M 23.27% -20.16M
Net non-operating interest income expense
2,250.00% 47K 1,800.00% 19K 0.00% 1K 102.00% 5K
Non-operating interest income
2,250.00% 47K 1,800.00% 19K 0.00% 1K -- --
Total other finance cost
-- -- -- -- -- -- -- -5K
Other net income (expense)
283.49% 600K
Gain on sale of security
-- -- -- -- -- -- 283.49% 600K
Income before tax
-9.39% -5.07M -25.69% -6.52M -3.30% -5.64M 27.17% -19.56M
Income tax
0 -34.28% -2.42M 15.29% -1.8M
Net income
-9.39% -5.07M -21.13% -4.11M -3.30% -5.64M 28.19% -17.76M
Net income continuous Operations
-9.39% -5.07M -21.13% -4.11M -3.30% -5.64M 28.19% -17.76M
Minority interest income
Net income attributable to the parent company
-9.39% -5.07M -21.13% -4.11M -3.30% -5.64M 28.19% -17.76M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-9.39% -5.07M -21.13% -4.11M -3.30% -5.64M 28.19% -17.76M
Basic earnings per share
-8.16% -0.53 -19.44% -0.43 -1.72% -0.59 41.01% -1.87
Diluted earnings per share
-8.16% -0.53 -19.44% -0.43 -1.72% -0.59 41.01% -1.87
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.
CEO: Mr. Peter Fernandes
Market: NASDAQ
Listing Date: 02/13/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist